Small molecule inhibitors of CXCL12-CXCR4 interaction
Modification of the body’s immune responses to tumor cells is a highly active area for oncology drug development. The current market for cancer immunotherapy is already a billion dollar market and is likely to expand to near $10 billion in the next decade. VIC has identified that AMD3100 (Plerixafor, Sanofi), a bicyclam CXCR4 antagonist approved for the mobilization of stem cells, has the potential to modulate immunosuppression by the tumor and contributes to prolonged survival in a normal immune mouse models of ovarian cancer and mesothelioma. The drug appears to decrease the population of T regulatory cells present in the tumor microenvironment, allowing the immune system to more effectively eliminate the tumor. VIC is investigating the use of this drug and its analogues in combination therapies for ovarian cancer and other solid tumors. VIC’s goal is to move AMD3100 into clinical trials for treatment of ovarian cancer in the next year and to identify optimal combination therapies for further development. VIC is collaborating with a new startup company on further development of this technology approach.